Connor, Clark & Lunn Investment Management (CC&L)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-9,611
| Closed | -$803K | – | 1642 |
|
|
2024
Q4 | $803K | Sell |
9,611
-7,488
| -44% | -$625K | ﹤0.01% | 1013 |
|
|
2024
Q3 | $1.25M | Buy |
+17,099
| New | +$1.25M | 0.01% | 811 |
|
|
2023
Q4 | – | Sell |
-26,161
| Closed | -$1.36M | – | 1598 |
|
|
2023
Q3 | $1.36M | Sell |
26,161
-10,734
| -29% | -$559K | 0.01% | 725 |
|
|
2023
Q2 | $2.34M | Buy |
36,895
+1,139
| +3% | +$72.1K | 0.01% | 571 |
|
|
2023
Q1 | $1.94M | Buy |
35,756
+18,159
| +103% | +$983K | 0.01% | 560 |
|
|
2022
Q4 | $931K | Buy |
17,597
+6,572
| +60% | +$348K | 0.01% | 724 |
|
|
2022
Q3 | $513K | Buy |
11,025
+772
| +8% | +$35.9K | ﹤0.01% | 813 |
|
|
2022
Q2 | $585K | Buy |
+10,253
| New | +$585K | ﹤0.01% | 741 |
|
|
2019
Q4 | – | Sell |
-26,556
| Closed | -$198K | – | 1121 |
|
|
2019
Q3 | $198K | Buy |
+26,556
| New | +$198K | ﹤0.01% | 867 |
|
|
2018
Q1 | – | Sell |
-11,425
| Closed | -$165K | – | 824 |
|
|
2017
Q4 | $165K | Buy |
+11,425
| New | +$165K | ﹤0.01% | 732 |
|